Alnylam Pharmaceuticals Reports Strong Q1 Earnings with Revenue Growth and Pipeline Expansion
Alnylam Pharmaceuticals reported a strong Q1 with $1.036 billion in combined net product revenues, driven by its TTR franchise. The company also expanded its TRITON-CM Phase III trial and reiterated 2026 revenue guidance. The stock saw a 65% increase following the earnings report.
Tickers: $ALNY
Topics: earnings financial performance pipeline development revenue growth TTR franchise